Table 1 Patient cohort characteristics for RP group and LDR group

Age(years)

 < 0.001

 Median

66

74

 Range

48–78

50–84

Clinical stage

N, %

0.002

 T1c

15 (9.4%)

42 (20.8%)

 T2a

40 (25.0%)

36 (17.9%)

 T2b

41 (25.6%)

32 (15.9%)

 T2c

64 (40.0%)

91 (45.2%)

PPBC

0.734

  ≤ 50%

125

154

  > 50%

35

47

Gleason Score

N, %

0.086

 6(3 + 3)

75 (46.8%)

79 (39.3%)

 7(3 + 4)

54 (33.7%)

63 (31.3%)

 7(4 + 3)

31 (19.3%)

59 (29.3%)

Prostate volume(ml)

0.172

  ≤ 30

76

110

  > 30

84

91

Initial PSA (ng/ml)

0.891

 Median

12.0

12.5

 Range

4.2–20.1

0.8–19.9

Risk

0.172

 Favorable

45

44

 Unfavorable

115

157

Follow-up, months

 < 0.001

 Median

54

69

 Range

17–114

26–117

Duration ADT, months

 < 0.001

 0

110

11

 1–6

25

94

  > 6

25

96

Adjuvant EBRT

15

5

 Risk level

 Favorable risk

45

44

 Unfavorable risk

115

157